Clinical trials: Portal Hypertension
Hepatocellular Carcinoma, Cirrhosis
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
- Trial name
- NCT05027425
- Testing
- Durvalumab, Tremelimumab, Liver Transplant
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Cincinnati
Liver Cirrhosis, Portal Hypertension
Probiotics for Liver Cirrhosis With Portal Hypertension
Recent studies indicate that probiotics can stimulate intestinal immunity and tighten the junctions of epithelial cells. By these ways, probiotics can reduce bacterial translocation; hence, they can ameliorate systemic…
- Trial name
- NCT01598064
- Testing
- GK#10
- Where
- Taiwan
- Volunteers
- 49 people
- Sponsor
- Po-Lin Chen, MD
Clinically Significant Portal Hypertension
The Effect of Sorafenib on Portal Pressure
Sorafenib is approved by the US FDA for the treatment of unresectable (can not operate) liver cancer and for renal cell carcinoma.
- Trial name
- NCT01714609
- Testing
- Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Yale University
End-stage Liver Disease (ESLD), Liver Transplant
A Physical Activity Program in End-state Liver Disease
The primary aim of this study is to improve both physical fitness and sarcopenia of patients with ESLD who are potentially eligible for liver transplantation through a 12-week physical training program.
- Conditions
- End-stage Liver Disease (ESLD), Liver Transplant, Sarcopenia, Poor Physical Fitness
- Trial name
- NCT02776553
- Testing
- Nutritional consultation, Physical training program, Behavioral modification therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Portal Hypertension
A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension
The purpose of this trial is to investigate safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) after intravenous (IV) administration of FE 204205 in patients with cirrhotic portal hypertension.
- Trial name
- NCT02929407
- Testing
- FE 204205
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Ferring Pharmaceuticals
Hypertension, Portal, Liver Cirrhosis
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes.
- Trial name
- NCT06082843
- Testing
- Avenciguat
- Where
- 15 sites in United States, Austria and 8 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Portal Hypertension
- Trial name
- NCT03439189
- Testing
- Methacetin Breath Test, Emricasan
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Meridian Bioscience, Inc.
Portal Hypertension, Liver Fibroses
Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness
Pilot study examining changes in liver stiffness measured by ultrasound before and after TIPS creation
- Trial name
- NCT03352882
- Testing
- Ultrasound
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Pennsylvania
Portopulmonary Hypertension
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
This is an Open Label, Multicenter, pilot clinical trial to assess the efficacy and safety of an oral selective Endothelin Receptor Antagonist (ambrisentan) in patients with portopulmonary hypertension.
- Trial name
- Portopulm (NCT01224210)
- Testing
- Ambrisentan
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tufts Medical Center
Esophageal Varices
Wired Magnetically Assisted Capsule Endoscopy and Esophageal Varices
The goal of this clinical trial is to compare the safeness and effectiveness of traditional esophagogastroduodenoscope (EGD) and wired magnetically assisted capsule endoscopy (MACE) in the diagnosis of esophageal varices in…
- Trial name
- NCT06017102
- Testing
- wired magnetic assisted capsule endoscopy, esophagogastroduodenoscopy
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Cirrhosis, Liver, Portal Hypertension
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
This is a randomized single-blind feasibility trial to test the utilization of home blood pressure devices to improve the clinical management of decompensated cirrhosis patients.
- Conditions
- Cirrhosis, Liver, Portal Hypertension, Ascites Hepatic
- Trial name
- WATCH (NCT05928624)
- Testing
- Withings Home Blood Pressure Device and Scale, Standard of Care
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of California, San Francisco
Patients With Compensated Liver Cirrhosis
Assessing Portal Hypertension With Methacetin Breath Test
This study will be used to train an algorithm using Methacetin breath test (MBT) measures and to select a cut-off to determine presence or absence of Clinically Significant Portal Hypertension (CSPH) as defined by Hepatic Venous…
- Trial name
- NCT02143778
- Testing
- Methacetin Breath Test
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 246 people
- Sponsor
- Meridian Bioscience, Inc.
Cirrhosis
A Trial to Improve Quality of Life in People With Cirrhosis
This trial is being completed to evaluate whether a crystallized form of lactulose (Kristalose) will improve quality of life, sleep and cognitive function in patients with cirrhosis that have not been diagnosed with Hepatic…
- Trial name
- NCT05061992
- Testing
- Lactulose
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Michigan
Compensated Cirrhosis and Portal Hypertension
An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
The main purpose of this exploratory study was to investigate the effect of serelaxin (RLX030) infusion on the hepatic and renal circulation in patients with compensated cirrhosis and portal hypertension.
- Trial name
- NCT01640964
- Testing
- Terlipressin acetate, Serelaxin (RLX030)
- Where
- United Kingdom
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Portal
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also…
- Trial name
- NASH-CX (NCT02462967)
- Testing
- GR-MD-02
- Where
- 46 sites in United States
- Volunteers
- 162 people
- Sponsor
- Galectin Therapeutics Inc.
Portal Hypertension, Chronic Advanced Liver Disease
Velacur by Sonic Incytes for Portal Hypertension
This is a cross sectional study that evaluates the relationship between LSM (liver stiffness measurement) by Liver Incytes in patients with cACLD (compensated advanced chronic liver disease) and manifestations of portal…
- Trial name
- NCT04576897
- Testing
- Velacur
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Indiana University
Liver Diseases, Portal Hypertension
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
This is an open-label, non-randomized trial that will be conducted at two clinical sites, Thomas Jefferson University (TJU) and the Hospital of the University of Pennsylvania (HUP).
- Trial name
- NCT02489045
- Testing
- SHAPE measurement (Sonazoid ultrasoud contrast agent)
- Where
- 2 sites in United States
- Volunteers
- 178 people
- Sponsor
- Thomas Jefferson University
Cirrhosis, Liver, Portal Hypertension
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis
This multicenter trial is being conducted to determine if sequential lactulose and Tele (virtual) Tai-Chi reduces the rate of injurious fall, non-injurious falls, incident overt Hepatic Encephalopathy (HE), and death or liver…
- Trial name
- NCT05794555
- Testing
- Enhanced Usual Care, Lactulose, Investigator recommended exercise
- Where
- 3 sites in United States
- Volunteers
- 233 people
- Sponsor
- University of Michigan
Liver Cirrhosis, Hepatic Cirrhosis
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
This is an open-label pilot study to evaluate the safety, tolerability, and efficacy of IDN-6556 in treating portal hypertension in subjects with liver cirrhosis.
- Conditions
- Liver Cirrhosis, Hepatic Cirrhosis, Portal Hypertension
- Trial name
- PH (NCT02230683)
- Testing
- IDN-6556
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Liver Diseases, Hypertension, Portal
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis caused by hepatitis B, hepatitis C or nonalcoholic steatohepatitis (NASH). People can join this study if they have high blood pressure in the portal vein (main vessel going to the…
- Trial name
- NCT05282121
- Testing
- Avenciguat, Empagliflozin
- Where
- 31 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim